Related Researcher

Author's Photo

Do, Yoonkyung
DC-based Immune System & Immunotherapy (DISNI) Lab
Research Interests
  • Study on various subsets of dendritic cells and their immunological functions
  • Vaccine development by targeting pathogenic antigens to distinct DC subsets via anti-DC-subset-specific-receptor monoclonal antibodies
  • Characterization of roles of DCs in tumor microenvironment and tumor metastasis
  • Studies on role of DCs in neuro-related diseases
  • Study DCs in collaboration with Biotechnology or Engineering field


Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor

DC Field Value Language Do, Yoonkyung ko Didierlaurent, Arnaud M. ko Ryu, Seongho ko Koh, Hyein ko Park, Chae Gyu ko Park, Steven ko Perlin, David S. ko Powell, Bradford S. ko Steinman, Ralph M. ko 2014-04-10T02:14:51Z - 2013-06-18 ko 2012-10 -
dc.identifier.citation VACCINE, v.30, no.45, pp.6359 - 6367 ko
dc.identifier.issn 0264-410X ko
dc.identifier.uri -
dc.identifier.uri ko
dc.description.abstract It is of great interest to develop a pneumonic plague vaccine that would induce combined humoral and cellular immunity in the lung. Here we investigate a novel approach based on targeting of dendritic cells using the DEC-205/CD205 receptor (DEC) via the intranasal route as way to improve mucosal cellular immunity to the vaccine. Intranasal administration of Yersinia pestis LcrV (V) protein fused to anti-DEC antibody together with poly IC as an adjuvant induced high frequencies of IFN-gamma secreting CD4(+) T cells in the airway and lung as well as pulmonary IgG and IgA antibodies. Anti-DEC:LcrV was more efficient to induce IFN-gamma/TNF-alpha/IL-2 secreting polyfunctional CD4(+) T cells when compared to non-targeted soluble protein vaccine. In addition, the intranasal route of immunization with anti-DEC:LcrV was associated with improved survival upon pulmonary challenge with the virulent CO92 Y. pestis. Taken together, these data indicate that targeting dendritic cells via the mucosal route is a potential new avenue for the development of a mucosal vaccine against pneumonic plague. ko
dc.description.statementofresponsibility close -
dc.language ENG ko
dc.publisher ELSEVIER SCI LTD ko
dc.subject CD205/DEC-205 ko
dc.subject Cellular immunity ko
dc.subject Dendritic cells ko
dc.subject LcrV ko
dc.subject Mucosal ko
dc.subject Y. pestis ko
dc.title Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor ko
dc.type ARTICLE ko
dc.identifier.scopusid 2-s2.0-84866547636 ko
dc.identifier.wosid 000310117200003 ko
dc.type.rims ART ko
dc.description.scopustc 7 * 2014-07-12 *
dc.identifier.doi 10.1016/j.vaccine.2012.08.051 ko
Appears in Collections:
BME_Journal Papers

find_unist can give you direct access to the published full text of this article. (UNISTARs only)

Show simple item record


  • mendeley


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.